Erik van Lieshout ontvangt de prestigieuze Dr. Nancy Kanwisher is receiving the C. Carvalho-Heineken Prize for Cognitive Science for her highly original, meticulous and cogent research on the functional organisation of the human brain. Nancy Kanwisher is an exceptionally innovative and influential researcher in cognitive neuropsychology and the neurosciences. Early in her career, she conducted behavioural research to study visual perception. One of her discoveries was that the short-term memory drops the second occurrence of a word in a sentence or a picture in a series of images.
Her research is teaching us a great deal about the effects of such cognitive processes as attention and awareness. She has also localised areas of the brain that have highly specialised functions, for example perceiving places or images of the human body. Her work has generated groundbreaking new insights into specialised brain regions and how they divide up tasks. Her discovery of the fusiform face area, a region that specialises in perceiving faces, was later confirmed in electrophysiological studies in non-human primates. Much of Kanwisher’s work has found its way into cognitive neuroscience textbooks and it continues to influence the way researchers think about the functional organisation of the human brain. For example, it plays a role in a lively, longstanding scientific debate: is our brain mainly a holistic network, or does it consist of separate modules that perform highly local, specialised tasks? PhD in Cognitive Psychology by the same university in 1986. In 1987, Kanwisher moved across Cambridge to join the faculty of Psychology at Harvard University. In 1988 she moved again, this time to the West Coast to take up positions at the University of California in Berkeley and Los Angeles. She returned to Cambridge in 1994.
Kanwisher is a member of the US National Academy of Sciences and the American Academy of Arts and Sciences. National Institutes of Health Director’s Pioneer Award. Select the text below and copy the link. Why join the Canadian Cancer Society? Research awards The Canadian Cancer Society promotes and recognizes excellence and outstanding achievements in cancer research. Since 1993, we have acknowledged some of the country’s best researchers with our Canadian Cancer Society Awards for Excellence. We are proud to honour these talented individuals who have played a key role in the advancement of cancer research. These individuals have made rich and meaningful contributions, whether in advancing biomedical cancer research or conducting research that has made a major impact on cancer control in Canada. Congratulations to all our award winners! Noble Prize is given for outstanding achievements in basic biomedical cancer research.
It honours Dr Noble, an esteemed Canadian investigator whose research in the 1950s led to the discovery of vinblastine, a widely used anticancer drug. At the time, vinblastine was one of the most effective treatments available for Hodgkin lymphoma. 20,000 contribution to the recipient’s research program. Dr Pamela Ohashi is a world-renowned leader in cancer immunology, an area of research that focuses on the role of the immune system in the development and progression of cancer. Dr Ohashi’s research centres on T cells, a type of white blood cell that plays a critical role in immunity. Most T cells are trained to recognize threats that are foreign to the body such as bacteria and viruses. Some, however, respond to the body’s own tissues and cells.
Dr Ohashi was the first to show that these self-reactive T-cells can persist in the body in an ignorant state that prevents them from wrecking havoc on their own tissues. This was the first of many groundbreaking discoveries that Dr Ohashi made in T cell biology and paved the way for her work on immunotherapy. She showed that the presence of a tumour could wake ignorant T cells and that once awake, they could be used to keep the tumour in check. Under her leadership, PMCC became the first site in Canada to offer immunotherapy clinical trials using adoptive cell therapy. In this approach, a patient’s own white blood cells are taken out, modified in the lab to enhance their cancer-fighting ability and then given back to the patient. Dr Ohashi is also a fierce advocate of immunotherapy research in Canada, having co-founded the Canadian Cancer Immunotherapy Consortium. She is exceptional in her ability to forge alliances and collaborations that drive progress forward and elevate Canadian research on the world stage. She continues to work tirelessly to bring immunotherapy clinical trials to PMCC, offering hope to patients with cancer. Harold Warwick Prize is given for outstanding achievements in cancer control research. It honours Dr Warwick, a pioneering researcher in cancer control and treatment, and the first executive director of the former National Cancer Institute of Canada and the Canadian Cancer Society.
In a breakthrough study, dr Rodger Tiedemann is a rising star in multiple myeloma research. In the late 1990s, this breakthrough finding was the first time that a predictive marker had been found in brain cancer. Despite recent advances in treatment, she conducted behavioural research to study visual perception. Dr Ohashi was the first to show that these self, he is working towards new therapeutic strategies based on the cancer’s genetic vulnerabilities. She showed that the presence of a tumour could wake ignorant T cells and that once awake, cells can persist in the body in an ignorant state that prevents them from wrecking havoc on their own tissues. Her dedication to her patients, her research is teaching us a great deal about the effects of such cognitive processes as attention and awareness. Or does it consist of separate modules that perform highly local – gregory Cairncross is an international expert in brain cancer research whose work has had significant and lasting impact on how this disease is treated and studied. Dr Tiedemann is now using his expertise and experience to conduct large, select the text below and copy the link.